Cargando…

Building a dedicated pediatric pulmonary hypertension program: A consensus statement from the pediatric pulmonary hypertension network

Pediatric pulmonary hypertension (PH) is a severe, life‐threatening disease associated with diverse cardiac, pulmonary, and systemic disorders, which generally requires expertise from multiple disciplines for management. Unfortunately, expert centers are limited, often due to inadequate resources or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Handler, Stephanie S., Varghese, Nidhy P., Rosenzweig, Erika B., Yung, Delphine, Krishnan, Usha, Whalen, Elise, Bates, Angela, Avitabile, Catherine M., Jackson, Emma O., Hirsch, Russel, Fineman, Jeffrey, Abman, Steven H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052968/ https://www.ncbi.nlm.nih.gov/pubmed/35506071 http://dx.doi.org/10.1002/pul2.12031

Ejemplares similares

Kids Mod PAH trial: A multicenter trial comparing mono‐ versus duo‐therapy for initial treatment of pediatric pulmonary hypertension
por: Collaco, Joseph M., et al.
Publicado: (2023)

Practice patterns of pulmonary hypertension secondary to left heart disease among pediatric pulmonary hypertension providers
por: Nawaytou, Hythem, et al.
Publicado: (2021)

Hereditary pulmonary arterial hypertension burden in pediatrics: A single referral center experience
por: Ishizuka, Maki, et al.
Publicado: (2023)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

Editorial: Advances in the care of the pediatric pulmonary hypertension patient: from the neonate to the adolescent-young adult patient
por: Avitabile, Catherine M., et al.
Publicado: (2023)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
por: Ivy, D. Dunbar, et al.
Publicado: (2019)

Prevalence of malnutrition in pediatric pulmonary hypertension cohort and role for registered dietitian involvement
por: Crowell, Presley R., et al.
Publicado: (2023)

Pulmonary Hypertension Associated with Bronchopulmonary Dysplasia: A Review
por: Varghese, Nidhy, et al.
Publicado: (2019)

Of Registries and Disease Classification: Unmasking the Challenges of Pediatric Pulmonary Hypertension
por: Abman, Steven H., et al.
Publicado: (2022)

Abnormal platelet aggregation in pediatric pulmonary hypertension
por: Handler, Stephanie S., et al.
Publicado: (2022)

Balloon atrial septostomy as initial therapy in pediatric pulmonary hypertension
por: Critser, Paul J., et al.
Publicado: (2020)

Multicenter mortality and morbidity associated with pulmonary hypertension in the pediatric intensive care unit
por: Balkin, Emily Morell, et al.
Publicado: (2017)

Assessment of quality of life in pediatric patients with pulmonary hypertension
por: Handler, Stephanie S., et al.
Publicado: (2018)

Caveolin‐1 associated with severe (pediatric‐onset) presentation of pulmonary arterial hypertension
por: Farrell, Rachel, et al.
Publicado: (2022)

Treatment of pediatric pulmonary hypertension
por: Hawkins, Amy, et al.
Publicado: (2009)

Editorial: Pediatric Pulmonary Hypertension
por: Beghetti, Maurice, et al.
Publicado: (2015)

Echocardiography in Pediatric Pulmonary Hypertension
por: Jone, Pei-Ni, et al.
Publicado: (2014)

Ventricular global function index is associated with clinical outcomes in pediatric pulmonary hypertension
por: Ta, Hieu T., et al.
Publicado: (2023)

The cascade screening in heritable forms of pulmonary arterial hypertension
por: Varghese, Nidhy P., et al.
Publicado: (2023)

Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease–Associated Pulmonary Hypertension
por: Daly, Caroline M., et al.
Publicado: (2021)

A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011
por: del Cerro, Maria Jesus, et al.
Publicado: (2011)

Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine
por: Douwes, Johannes M., et al.
Publicado: (2022)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

Vasoreactive phenotype in children with pulmonary arterial hypertension and syncope
por: Linder, Alexandra N., et al.
Publicado: (2022)

Change in Pediatric Functional Classification During Treatment and Morbidity and Mortality in Children with Pulmonary Hypertension
por: Balkin, Emily Morell, et al.
Publicado: (2016)

Sildenafil in pediatric pulmonary arterial hypertension
por: Dhariwal, AK, et al.
Publicado: (2015)

Skeletal muscle deficits are associated with worse exercise performance in pediatric pulmonary hypertension
por: Avitabile, Catherine M., et al.
Publicado: (2022)

Targeted Therapy for Pulmonary Hypertension in Premature Infants
por: Nees, Shannon N., et al.
Publicado: (2020)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
por: McSweeney, Julia, et al.
Publicado: (2023)

Pediatric Pulmonary Hypertension: Insulin Like Growth Factor Binding Protein 2 is a novel marker associated with disease severity and survival
por: Griffiths, Megan, et al.
Publicado: (2020)

Genetics and Genomics of Pediatric Pulmonary Arterial Hypertension
por: Welch, Carrie L., et al.
Publicado: (2020)

Pulmonary Hypertension as a Complication of Pediatric Cancer
por: Kirkpatrick, Edward C.
Publicado: (2021)

Factors leading to supranormal cardiac index in pediatric pulmonary hypertension patients treated with parenteral prostanoid therapy
por: Miles, Kimberley G., et al.
Publicado: (2023)

Adverse drug event rates in pediatric pulmonary hypertension: a comparison of real-world data sources
por: Geva, Alon, et al.
Publicado: (2019)

Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension
por: Nikkho, Sylvia M., et al.
Publicado: (2022)

Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report
por: Wang, Guoliang, et al.
Publicado: (2016)

Impaired NO-cGMP signaling in the pathogenesis of neonatal pulmonary hypertension and therapeutic implications
por: Abman, Steve H
Publicado: (2009)

Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management
por: Rosenzweig, Erika B., et al.
Publicado: (2019)

Circulating Cytokines and Growth Factors in Pediatric Pulmonary Hypertension
por: Duncan, Mark, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_efktbr94bde9qve3jljlovnj8v